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fractions. Treatments were planned on Eclipse software (Varian 
Medical Systems, Inc) using 7-9 static fields or two volumetric 
modulated arcs for delivery on Varian linacs. Kilovoltage free 
breathing CBCTs were taken both for initial patient positioning 
and also immediately after treatment. The pre- and post-
treatment CBCTs were compared to confirm that the lung tumour 
remained inside the PTV and to assess the stability and the 
suitability of the PTV margin used. Comparisons were performed 
using a visual match by at least two experienced professionals in 
Varian’s Offline Review software. The time interval between 
both CBCTs was extracted trying to have a measure of the 
treatment time. 
Results: There were 44 cases/treatments with pre- and post-
treatment CBCTs reviewed. The mean time between the CBCTs 
(treatment time) was 16.5 ± 6 minutes (range: 10 to 34 minutes). 
In all cases the tumour was appropriately kept inside the PTV in 
the post-treatment CBCT. The mean corrections between pre 
and post-treatment CBCTs were -0.7 ± 1.6 mm (range -5.0 to 3.0 
mm) vertically, -0.3 ± 1.7 mm (range -4.8 to 3.0 mm) 
longitudinally, and -0.4 ± 1.5 mm (range -4.0 to 2.0 mm) 
laterally. 
Conclusions: There was no tumour displaced outside the PTV 
even during relatively slow SBRT delivery in all our lung cancer 
patients treated with SBRT without any customized 
immobilization. For our cohort of patients, the PTV margin (5 
mm) used was consistent with the measured residual intra-
fraction motion, also reported in other studies. This experience 
goes along with the growing trend in frameless, free-breathing 
SBRT for lung tumours. 
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Purpose: Obtaining a proper specimen for diagnostic pathology 
and genetic analysis can be challenging in some patients. The 
purpose of this study was to examine the diagnostic yield for 
different specimen types submitted for epidermal growth factor 
receptor (EGFR) mutation testing in patients with metastatic 
non-small cell lung cancer (NSCLC). 
Methods and Materials: A multicentre retrospective study was 
conducted of patients with a pathologic diagnosis of metastatic, 
non-squamous, NSCLC for the period 2010 to 2012. Patients were 
identified using a provincial cancer registry. Data was collected 
on patient characteristics, biopsy characteristics, and diagnostic 
outcome. All EGFR testing was done at a central lab for exon 19 
deletions and exon 21 mutations. 
Results: For 1499 patients, the pathologic diagnosis was 
determined from histology in 945 and cytology in 554. Six 
hundred twenty-seven (41.8%) of these patients had EGFR 
mutation testing. Mutation testing was requested in a higher 
proportion of patients with histology compared to those with 
cytology, 48.6% (459/945) versus 30.3% (168/554), respectively 
(p < 0.001). In patients with histology the diagnostic yield was 
88.2% (19.8% EGFR+; 68.4% EGFR wild type (WT); 11.8% non-
diagnostic). In patients with cytology the diagnostic yield was 
82.1% (17.9% EGFR+; 64.3% EGFR WT; 17.9% non-diagnostic). 
There was no statistically significant difference in diagnostic 
yield (p = 0.063) or mutation rates (p = 0.86) between the two 
specimen types. The histology and cytology cohorts were no 
different for age (p = 0.10), ECOG performance status (p = 0.39), 
and gender (p = 0.24). By location, specimens were obtained 
from the primary tumour in 317 (50.6%), thoracic lymph node in 
87 (13.9%), metastatic site in 158 (25.2%), and pleura/pleural 
fluid in 65 (10.4%). The diagnostic yields from these sites were 
84%, 87%, 91%, and 97%, respectively. 
Conclusions: For EGFR mutation testing, oncologists should not 
feel limited by biopsy site or specimen type. Cytology is 
sufficient for testing in most patients, and the diagnostic yield is 
comparable to histology. 
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Purpose: Miliary metastases arise from widespread 
hematogenous disease dissemination and are characterized by 
metastatic nodules that are diffuse, innumerable and small. The 
purpose of this study was to examine the incidence, prognostic 
significance, and impact of epidermal growth factor receptor 
(EGFR) mutations for miliary metastases from non-small cell lung 
cancer (NSCLC). 
Methods and Materials: Patients were identified from a 
Provincial cancer registry (British Columbia, Canada) for the 
period 2010-2012. Inclusion criteria were Stage IV NSCLC at 
initial presentation and conclusive EGFR mutation testing (for 
exons 19 and 21). Miliary metastases for each organ site were 
objectively defined as > 15 metastatic nodules of < 1 cm 
diameter size involving more than one organ lobe and bilaterally 
distributed. The primary endpoint was the association between 
EGFR mutations and miliary lung, brain, and liver metastases. 
The significance of EGFR mutation status and miliary metastases 
on survival were assessed using the Cox proportional hazards 
model. 
Results: For 543 patients, 422 (77.7%) were EGFR wild type (WT) 
and 121 (22.3%) EGFR mutation positive (EGFR+). Six (1.1%) 
patients had miliary brain metastases: two (0.5%) EGFR WT and 
four (3.3%) EGFR+ (exon 19 = 4; exon 21 = 0). Patients with an 
exon 19 mutation had a significantly higher incidence of miliary 
brain metastases compared to EGFR WT (p = 0.005). Twenty-nine 
(5.3%) patients had miliary lung metastases: 15 (3.6%) EGFR WT 
and 14 (11.6%) EGFR+ (exon 19 = 8; exon 21 = 6). Patients with 
EGFR+ status had a significantly higher incidence of miliary lung 
metastases compared to EGFR WT (p = 0.002). There was no 
difference in miliary lung metastases between exon subtypes (p 
= 0.78). Two (0.4%) patients had miliary liver metastases: two 
(0.5%) EGFR WT and none EGFR+. In multivariate analysis (MVA), 
miliary (versus non-miliary) brain (p = 0.47) and lung (p = 0.64) 
metastases were not significant factors for survival. EGFR+ status 
was significant for longer survival (p = 0.001) in MVA. 
Conclusions: Mutations in EGFR predispose to miliary brain and 
lung metastases. The survival outcome of patients with military 
brain and lung metastases is not adverse compared to non-
miliary metastases. 
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Purpose:  One of the purported advantages of SABR as an 
alternative treatment option to surgery for early-stage non-small 
cell lung cancer (ES-NSCLC) is health-related quality of life 
(HRQOL). The purpose of this study is to 1) perform a systematic 
review of HRQOL following SABR for ES-NSCLC and 2) to describe 
HRQOL and indirect costing outcomes from the ROSEL 
randomized trial comparing surgery and SABR for ES-NSCLC. 
Methods and Materials:  In ROSEL, 22 patients with ES-NSCLC 
were randomized to SABR or surgery before the trial closed due 
to poor accrual. HRQOL was evaluated at baseline, and then 
three, six, 12, 18, and 24 months post-treatment using the 30 
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item EORTC QLQ-C30, its corresponding 13-item lung cancer 
supplement, and the EuroQol disease-generic questionnaire. 
Indirect costs of productivity loss were evaluated using the short 
form health and labor questionnaire, which includes work 
absences, reduced efficiency at work, and substitution for 
unpaid work. Time to deterioration (TTD) in HRQOL was 
calculated from time to randomization to first appearance of 
clinically significant change. TTD was analyzed using Cox 
proportional hazard models. The Embase and MEDLINE databases 
were systematically reviewed to obtain English language articles 
investigating patient-reported HRQOL after SABR for ES-NSCLC 
up to August 1, 2015. Review articles, meta-analyses and 
decision analyses were excluded. Relevant data regarding 
patient characteristics and study outcomes were abstracted and 
analyzed. 
Results:  In the ROSEL study, only TTD of global health status 
was significantly worse on univariable modeling for surgical 
patients compared to SABR (HR 0.19, p = 0.038). Indirect costing 
analysis revealed lower total productivity costs to society for 
SABR compared to surgery (€95 versus and €3,513, p = 0.044). 
Patients reported a lower total degree of hindrance in paid and 
unpaid work for SABR compared to surgery (mean hindrance 
scores for SABR: 1.9, for surgery: 6.0, p = 0.010). In the 
systematic review, nine out of 204 potential studies met all 
inclusion criteria and were analyzed. All studies were 
prospective in design. Overall SABR appeared to be well-
tolerated, in a mostly medically inoperable patient population. 
Clinically and statistically significant deteriorations in fatigue 
and dyspnea were individually reported in two studies. An 
isolated report found clinically and statistically significant 
improvements in emotional functioning over time. Deterioration 
in dyspnea and physical functioning were noted in other studies, 
but were neither statistically nor clinically significant. 
Conclusions:  SABR is an overall well-tolerated modality in 
patients with ES-NSCLC who either declined surgery or were 
unfit. Exploratory results in operable ES-NSCLC suggest that SABR 
may be better tolerated than surgery and incur indirect costing 
savings. Future clinical trials comparing SABR and surgery would 
benefit from the inclusion of HRQOL metrics in study design. 
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Purpose: In patients undergoing surgery for Stage I NSCLC, the 
delivery of neoadjuvant SABR has been proposed as a method of 
improving oncologic outcomes. A Phase II trial was launched to 
evaluate oncologic outcomes, pCR rates, and toxicity after SABR 
followed by surgical resection. The protocol mandated an 
interim safety analysis after completion of combined treatment 
in the first 10 patients. 
Methods and Materials: Operable patients with biopsy-proven 
T1T2N0 NSCLC were eligible. SABR was delivered using a risk-
adapted fractionation (54 Gy/3 fractions, 55/5 fractions or 60/8 
fractions, all with biologically effective dose > 100 Gy10), 
prescribed to the ~80% isodose line covering the planning target 
volume. Surgical resection was planned 10 weeks later, either 
lobectomy or sublobar resection, at a high-volume tertiary 
centre completing more than 200 lung cancer resections 
annually. Patients were imaged with dynamic FDG-PET CT and 
dynamic contrast enhanced CT before SABR and again before 
surgery. Toxicity was recorded using CTCAE version 4.0. 
Results: Twelve patients were enrolled between September 2014 
and September 2015. Two did not undergo surgery after SABR 
due to patient or surgeon preference; neither patient has 
developed toxicity or recurrence. For the 10 patients completing 
both treatments, median age was 70 (range 54-76), 60% had T1 
disease, and 60% had adenocarcinoma. Median FEV1 was 73% 
predicted (range 54-87%). Median time to surgery post-SABR was 
10.1 weeks (range 9.3-15.6 weeks). Surgery consisted of 
lobectomy (n = 8) or wedge resection (n = 2). Median follow up 
post-SABR was 6.3 months. After combined treatment, the rate 
of Grade 3-4 toxicity was 10% (one patient with pneumonia, atrial 
fibrillation, and respiratory failure [post-operative re-intubation 
due to mucus plugging], all resolved). Seven patients developed 
Grade 2 toxicities. Thirty- and 90-day mortality post-surgery 
were both 0%. 
Conclusions: Toxicity rates after SABR + surgical resection 
compare very favourably with reported rates in prospective 
studies of surgical resection alone (~48% Grade 3-5 toxicity after 
lobectomy [1] and ~30% after wedge resection [2]). Mature data 
on pCR rates and oncologic outcomes from this combined 
modality strategy are awaited. 
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Purpose: SBRT is an alternative treatment to surgery for Stage I 
NSCLC. Intriguingly, NSCLC lesions post-SBRT rarely exhibit a 
complete response locally and yet yield excellent local control 
of around 95%. The degree of treatment response seems to have 
little effect on in current practice. This study investigated 
tumour response post-SBRT as a clinical outcomes predictor in 
Stage I NSCLC patients. 
Methods: Survival outcomes of 233 patients were reviewed 
retrospectively from Sunnybrook Electronic Patient Record. 
Tumour sizes were collected from radiologist’s measurements 
based on CT-Scan pre and post-SBRT within 6, 12, and 18 months 
intervals. Each patient’s maximum response within 18 months 
was calculated and grouped using RECIST 1.1 methodology: 
complete response (CR), partial response (PR), stable disease 
(SD), and progressive disease (PD). 
Results: The median age of study population was 77.5 years. 
Median follow up duration was 25 months. Local control (LC), 
overall survival (OS), and non-local control (NLC) for all patients 
at two years were: 92.5, 74.6, and 68.0% respectively. Of 
patients with available pre and post-SBRT tumour sizes (n = 188), 
11 (5.9%), 92 (48.9%), 79 (42.0%), and six (3.2%) patients were 
categorized CR, PR, SD, and PD respectively using RECIST 1.1 
methodology. LC were: CR (100%), PR (94.0%), SD (89.7%), and 
PD (66.7%) respectively after two years. OS were: CR (80.0%), PR 
(80.8%), SD (72.0%), and PD (44.4%) respectively. NLC were: CR 
(100%), PR (66.4%), SD (62.5%) and PD (16.7%) respectively. 
There is a statistically significant difference in NLC between 
groups (p = 0.0009). 
Conclusions: Stage I NSCLC patients with a lesser response post-
SBRT are at higher risk of developing non-local recurrences. 
These patients may benefit from closer follow up and adjuvant 
treatment post-SBRT. 
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